TY - JOUR
T1 - The effect of special diets on weight and nutritional intake in hematological cancer patients
T2 - A randomized study
AU - Bille, Sanne J
AU - Fjalstad, Benedicte W
AU - Clausen, Mette Borg
AU - Andreasen, Bent J
AU - Andersen, Jens Rikardt
N1 - CURIS 2018 NEXS 279
PY - 2018/8/18
Y1 - 2018/8/18
N2 - Major weight loss and taste changes are well documented in patients with hematological cancer during chemotherapy. We have previously documented, that such patients have preferences for much umami, a little sweet, sour and salt, and no bitter. We wanted to convert these results into real diets. Patients participated in two sensory pilot studies (n = 10), where dishes were tested for preferences before and after chemotherapy. From these results, four dishes were selected and tested on 32 patients in 30 days in a cross-over design. The diets resulted in a beneficial and statistically significant difference in weight development (p = 0.0008), with 1.2 ± 1.9 kg (+2%) in the intervention period and -2.8 ± 5.2 kg (-4%) in the control period. This difference persisted after sensitivity analysis (±10%) P = 0.005. However, the nutritional intake was still low in both periods, and the treatment with cytarabine turned out to be a major confounder as dosage was significantly higher in the control period.
AB - Major weight loss and taste changes are well documented in patients with hematological cancer during chemotherapy. We have previously documented, that such patients have preferences for much umami, a little sweet, sour and salt, and no bitter. We wanted to convert these results into real diets. Patients participated in two sensory pilot studies (n = 10), where dishes were tested for preferences before and after chemotherapy. From these results, four dishes were selected and tested on 32 patients in 30 days in a cross-over design. The diets resulted in a beneficial and statistically significant difference in weight development (p = 0.0008), with 1.2 ± 1.9 kg (+2%) in the intervention period and -2.8 ± 5.2 kg (-4%) in the control period. This difference persisted after sensitivity analysis (±10%) P = 0.005. However, the nutritional intake was still low in both periods, and the treatment with cytarabine turned out to be a major confounder as dosage was significantly higher in the control period.
U2 - 10.1080/01635581.2018.1490446
DO - 10.1080/01635581.2018.1490446
M3 - Journal article
C2 - 30080980
SN - 0163-5581
VL - 70
SP - 874
EP - 878
JO - Nutrition and Cancer
JF - Nutrition and Cancer
IS - 6
ER -
